A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
The purpose of this study is to find out the side effects, good and/or bad, of the study drug, INCB052793, at different doses and in combination with other standard therapies in individuals with advanced malignancies (cancer).
Multiple myeloma, acute myeloid leukemia (AML), and myelodsyplastic syndromes (MDS)
Patients who have been diagnosed with multiple myeloma (MM), acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) who have failed, or are refractory to, available treatments.
18 - 99
Healthy Volunteers Needed
Duration of Participation
You will receive study treatment for as long as you do not experience serious side effects and as long as your cancer does not get worse. If it becomes appropriate to discontinue study treatment the investigator will continue to monitor you for up to 35 days after the last dose of study drug and will continue to collect information from you every three months indefinitely.
Clinical Trials Information Line